Merck, 699852P-1MG, 3D-PHAD™</SUP>

General description
Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD™), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.
Application
3D-PHAD™ has been used:
as a synthetic adjuvant for respiratory syncytial virus (RSV) vaccine
as a synthetic adjuvant to prepare hepatitis B virus (HBV) and virus-like particles (VLP)-based human papillomavirus (HPV) vaccines
in liposome preparation for the generation of army liposome formulation (ALF) for human immunodeficiency (HIV) gp140 antigen immunization studies in mice.

Biochem/physiol Actions
3-deacyl-phosphorylated hexa-acyl disaccharide (3D-PHAD™) is derived from monophosphoryl lipid A. It is amphiphilic and associates with the virosomal membranes.
Features and Benefits
The highly pure MPLA analog, 3D-PHAD™, provides a homogeneous synthetic equivalent for the 3-deacylated MPLA derived from bacterial LPS. 3D-PHAD™ is less pyrogenic than its bacterial-derived mimic while eliciting a comparable response to other MPLA analogs.
Packaging
2 mL Amber Glass Crimp Cap Vial (699852P-1mg)
2 mL Amber Glass Crimp Cap Vial (699852P-5mg)
Other Notes
For R&D use only. Not for drug, household, or other uses.
Legal Information
3D-PHAD is a trademark of Avanti Polar Lipids, LLC
Avanti Research is a trademark of Avanti Polar Lipids, LLC
PHAD is a trademark of Avanti Polar Lipids, LLC